Pasar al contenido principal

ESTRUCTURA, REGULACION Y BUSQUEDA DE DIANAS FARMACOLOGICAS DE LAS PROTEINAS DE SEÑALIZACION EN ADHESIONES FOCALES

RTI2018-099318-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Structural basis of Focal Adhesion Kinase activation on lipid membranes

  • Acebrón, Iván
  • Righetto, Ricardo D.
  • Schoenherr, Christina
  • de Buhr, Svenja
  • Redondo, Pilar
  • Culley, Jayne
  • Rodríguez, Carlos F.
  • Daday, Csaba
  • Biyani, Nikhil
  • Llorca, Óscar
  • Byron, Adam
  • Chami, Mohamed
  • Gräter, Frauke
  • Boskovic, Jasminka
  • Frame, Margaret C.
  • Stahlberg, Henning
  • Lietha, Daniel
21 p.-9 fig.-2 tab., Focal adhesion kinase (FAK) is a key component of the membrane proximal signaling layer in focal adhesion complexes, regulating important cellular processes, including cell migration, proliferation, and survival. In the cytosol, FAK adopts an autoinhibited state but is activated upon recruitment into focal adhesions, yet how this occurs or what induces structural changes is unknown. Here, we employ cryo-electron microscopy to reveal how FAK associates with lipid membranes and how membrane interactions unlock FAK autoinhibition to promote activation. Intriguingly, initial binding of FAK to the membrane causes steric clashes that release the kinase domain from autoinhibition, allowing it to undergo a large conformational change and interact itself with the membrane in an orientation that places the active site toward the membrane. In this conformation, the autophosphorylation site is exposed and multiple interfaces align to promote FAK oligomerization on the membrane. We show that interfaces responsible for initial dimerization and membrane attachment are essential for FAK autophosphorylation and resulting cellular activity including cancer cell invasion, while stable FAK oligomerization appears to be needed for optimal cancer cell proliferation in an anchorage-independent manner. Together, our data provide structural details of a key membrane bound state of FAK that is primed for efficient autophosphorylation and activation, hence revealing the critical event in integrin mediated FAK activation and signaling at focal adhesions., I.A. acknowledges support from the José Castillejo Mobility Grant issued by the Spanish Ministry of Education, Culture and Sports. R.D.R. acknowledges funding from the Fellowships for Excellence program sponsored by the Werner-Siemens Foundation and the University of Basel.H.S. acknowledges support by the Swiss National Science Foundation(grants 205320_166164 and 185544 (NCCR TransCure)). M.C.F., A.B., J.C., and C.S. were supported by a Cancer Research UK Programme Grant (C157/ A24837) to M.C.F. F.G. acknowledges funding by the Klaus Tschira Foundation, by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy – 2082/1 –390761711, and the state of Baden-Württemberg through bwHPC and the DFG through grant INST 35/11341 FUGG.S.d.B. thanks the Carl Zeiss Foundation for financial support. D.L. acknowledges support from the Spanish Ministry of Economy, Industry and Competitiveness for the Retos Grant BFU2016-77665-R and the Ministry of Science, Innovation and Universities for the Spanish State Research Agency Retos Grant RTI2018-099318-B-I00,both co-funded by the European Regional Development Fund (FEDER) and from an intramural grant from the Spanish National Research Council(CSIC, Ref: 201820I124). O.L. is funded by SAF2017-82632-P grant from the Spanish Ministry of Science, Innovation and Universities (MCIU/AEI), cofunded by the European Regional Development Fund (ERDF), by the National Institute of Health Carlos III and by projects Y2018/BIO4747 and P2018/NMT4443 from the Autonomous Region of Madrid and co-funded by the European Social Fund and the European Regional Development Fund. C.F.R. is funded by a BES-2015-071348 PhD fellowship by the Spanish Ministry of Science, Innovation and Universities (MCIU/AEI)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Design, synthesis and biological evaluations of covalent inhibitors of Focal Adhesion Kinase (FAK) against human malignant glioblastoma

  • Li, Bo
  • Li, Yongliang
  • Tomkiewicz-Raulet, Céline
  • Dao, Pascal
  • Lietha, Daniel
  • Yen-Pon, Expédite
  • Du, Zhiyun
  • Coumoul, Xavier
  • Garbay, Christiane
  • Etheve-Quelquejeu, Mélanie
  • Chen, Huixiong
66 p.-7 fig.-4 tab.-3 schem., Human malignant glioblastoma (GBM) is a highly invasive and lethal brain tumor. Targeting of integrin downstream signaling mediators in GBM such as focal adhesion kinase (FAK) seems reasonable and recently demonstrated promising results in early clinical studies. Herein, we report the structure-guided development of a series of covalent inhibitors of FAK. These new compounds displayed highly potent inhibitory potency against FAK enzymatic activity with IC50 values in the nanomolar range. Several inhibitors retarded tumor cell growth as assessed by a cell viability assay in multiple human glioblastoma cell lines. They also significantly reduced the rate of U-87 cell migration and delayed the cell cycle progression by stopping cells in the G2/M phase. Furthermore, these inhibitors showed a potent decrease of autophosphorylation of FAK in glioblastoma cells and its downstream effectors Akt and Erk as well as nuclear factor-κB. These data demonstrated that these inhibitors may have the potential to offer a promising new targeted therapy for human glioblastomas., We gratefully thank the support from la Ligue contre le cancer Paris Ile-de-France. BL thanks the China Scholarship Council (CSC) for financial support.YL thanks the support from National Natural Science Foundation of China (Grants 21672043). DL acknowledges support from Spanish Ministry of Economy, Industry and Competitiveness for the Retos Grant BFU2016-77665-R and the Ministry of Science, Innovation and Universities for the Spanish State Research Agency Retos Grant RTI2018-099318-B-I00, both cofunded by the European Regional Development Fund (FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

FAK structure and regulation by membrane interactions and force in focal adhesions

  • Tapial Martínez, Paula
  • López-Navajas, Pilar
  • Lietha, Daniel
16 p.-2 fig., Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase with key roles in the regulation of cell adhesion migration, proliferation and survival. In cancer FAK is a major driver of invasion and metastasis and its upregulation is associated with poor patient prognosis. FAK is autoinhibited in the cytosol, but activated upon localisation into a protein complex, known as focal adhesion complex. This complex forms upon cell adhesion to the extracellular matrix (ECM) at the cytoplasmic side of the plasma membrane at sites of ECM attachment. FAK is anchored to the complex via multiple sites, including direct interactions with specific membrane lipids and connector proteins that attach focal adhesions to the actin cytoskeleton. In migrating cells, the contraction of actomyosin stress fibres attached to the focal adhesion complex apply a force to the complex, which is likely transmitted to the FAK protein, causing stretching of the FAK molecule. In this review we discuss the current knowledge of the FAK structure and how specific structural features are involved in the regulation of FAK signalling. We focus on two major regulatory mechanisms known to contribute to FAK activation, namely interactions with membrane lipids and stretching forces applied to FAK, and discuss how they might induce structural changes that facilitate FAK activation., D.L. is funded by the Spanish Ministry of Economy, Industry and Competitiveness for the Retos Grant BFU2016-77665-R and the Ministry of Science, Innovation and Universities for the Spanish State Research Agency Retos Grant RTI2018-099318-B-I00, both cofunded by the European Regional Development Fund (FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ORP2 couples LDL-cholesterol transport to FAKactivation by endosomal cholesterol/PI(4,5)P2exchange

  • Takahashi, Kohta
  • Kanerva, Kristiina
  • Vanharanta, Lauri
  • Almeida-Souza, Leonardo
  • Lietha, Daniel
  • Olkkonen, Vesa M.
  • Ikonen, Elina
20 p.-8 fig., Low-density lipoprotein (LDL)-cholesterol delivery from late endosomes to the plasma membrane regulates focal adhesion dynamics and cell migration, but the mechanisms controlling it are poorly characterized. Here, we employed auxin-inducible rapid degradation of oxysterol-binding protein-related protein 2 (ORP2/OSBPL2) to show that endogenous ORP2 mediates the transfer of LDL-derived cholesterol from late endosomes to focal adhesion kinase (FAK)-/integrin-positive recycling endosomes in human cells. In vitro, cholesterol enhances membrane association of FAK to PI(4,5)P2-containing lipid bilayers. In cells, ORP2 stimulates FAK activation and PI(4,5)P2 generation in endomembranes, enhancing cell adhesion. Moreover, ORP2 increases PI(4,5)P2 in NPC1-containing late endosomes in a FAK-dependent manner, controlling their tubulovesicular trafficking. Together, these results provide evidence that ORP2 controls FAK activation and LDL-cholesterol plasma membrane delivery by promoting bidirectional cholesterol/PI(4,5)P2 exchange between late and recycling endosomes., This study was supported by the Academy of Finland (grants 307415 and 324929 to E.I., 322647 to V.M.O.), Sigrid Juselius Foundation (E.I., V.M.O., L. A.-S.), Fondation Leducq (grant 19CVD04) (E.I.), Jane and Aatos Erkko Foundation (E.I.), Magnus Ehrnrooth Foundation (K.T., V.M.O.), and the Finnish Foundation for Cardiovascular Research (V.M.O.). L.-A.S. acknowledges support from Helsinki Institute of Life Science (HiLIFE, start-up grant) and D.L. from the Ministry of Science, Innovation and Universities for the Spanish State Research Agency Retos Grant RTI2018-099318-B-I00, cofounded by the European Regional Development Fund (FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A new layer of phosphoinositide-mediated allosteric regulation uncovered for SHIP2

  • Le Coq, Johanne
  • López-Navajas, Pilar
  • Rodrigo Martín, Bárbara
  • Alfonso, Carlos
  • Lietha, Daniel
12 p.-5 fig.-1 tab., The Src homology 2 containing inositol 5-phosphatase 2 (SHIP2) is a large multidomain enzyme that catalyzes the dephosphorylation of the phospholipid phosphatidylinositol 3,4,5-triphosphate (PI(3,4,5)P3) to form PI(3,4)P2. PI(3,4,5)P3 is a key lipid second messenger controlling the recruitment of signaling proteins to the plasma membrane, thereby regulating a plethora of cellular events, including proliferation, growth, apoptosis, and cytoskeletal rearrangements. SHIP2, alongside PI3K and PTEN, regulates PI(3,4,5)P3 levels at the plasma membrane and has been heavily implicated in serious diseases such as cancer and type 2 diabetes; however, many aspects of its regulation mechanism remain elusive. We recently reported an activating effect of the SHIP2 C2 domain and here we describe an additional layer of regulation via the pleckstrin homology-related (PHR) domain. We show a phosphoinositide-induced transition to a high activity state of the enzyme that increases phosphatase activity up to 10-15 fold. We further show that PI(3,4)P2 directly interacts with the PHR domain to trigger this allosteric activation. Modeling of the PHR-phosphatase-C2 region of SHIP2 on the membrane suggests no major inter-domain interactions with the PHR domain, but close contacts between the two linkers offer a possible path of allosteric communication. Together, our data show that the PHR domain acts as an allosteric module regulating the catalytic activity of SHIP2 in response to specific phosphoinositide levels in the cell membrane., DL acknowledges support from the Spanish Ministry of Science, Innovation and Universities for the Spanish State Research Agency Retos Grant RTI2018-099318-B-I00, cofunded by the European Regional Development Fund (FEDER). CA is supported by the Spanish Ministry of Science and Innovation Grant PID2019-104544GB-I00., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A conformation selective mode of inhibiting SRC improves drug efficacy and tolerability, Running title: New mode of inhibiting SRC improves drug properties

  • Temps, Caroline
  • Lietha, Daniel
  • Webb, Emily R.
  • Li, Xue-Feng
  • Dawson, John C.
  • Muir, Morwenna
  • Macleod, Kenneth G.
  • Valero, Teresa
  • Munro, Alison F.
  • Contreras-Montoya, Rafael
  • Luque-Ortega, Juan Román
  • Fraser, Craig
  • Beetham, Henry
  • Schoenherr, Christina
  • Lopalco, Maria
  • Arends, Mark J.
  • Frame, Margaret C.
  • Qian, Bin-Zhi
  • Brunton, Valerie G.
  • Carragher, Neil O.
  • Unciti-Broceta, Asier
14 p.-5 fig., Despite the approval of several multikinase inhibitors that target SRC and the overwhelming evidence of the role of SRC in the progression and resistance mechanisms of many solid malignancies, inhibition of its kinase activity has thus far failed to improve patient outcomes. Here we report the small molecule eCF506 locks SRC in its native inactive conformation, thereby inhibiting both enzymatic and scaffolding functions that prevent phosphorylation and complex formation with its partner FAK. This unprecedented mechanism of action resulted in highly potent and selective pathway inhibition, in culture and in vivo. Treatment with eCF506 resulted in increased antitumor efficacy and tolerability in syngeneic murine cancer models, demonstrating significant therapeutic advantages over existing SRC/ABL inhibitors. Therefore, this novel mode of inhibiting SRC could lead to improved treatment of SRC-associated disorders., C.T. thanks the CMVM of the University of Edinburgh (Principal's scholarship). D.L. acknowledges support from the Spanish Ministry of Science, Innovation and Universities for the Spanish State Research Agency Retos Grant RTI2018-099318-B-I00, cofunded by the European Regional Development Fund (FEDER). E.R.W., J.C.D. and K.G.M. are funded by CRUK. J.R.L.O. acknowledges support from the Molecular Interactions Facility funds at the CIB-CSIC. T.V. is funded by H2020-MSCA-IF-2016-749299. RCM thanks the support from the Vice Rectorate for Research of the University of Granada. X.-F.L. and B.-Z.Q. are funded by a CRUK Career Development Fellowship (C49791/A17367). B.-Z.Q. also acknowledges support from an ERC Starting Grant (716379). C.S, M.C.F. and V.G.B are funded by CRUK Programme Grant C157/A15703. N.O.C. and A.U.B are grateful to the CMVM of the University of Edinburgh and Wellcome Trust for financial support (ISSF3)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

TDP-43 modulation by Tau-Tubulin kinase 1 inhibitors: A new avenue for future amyotrophic lateral sclerosis therapy

  • Nozal, Vanesa
  • Martínez-González, Loreto
  • Gómez-Almería, Marta
  • Gonzalo-Consuegra, Claudia
  • Santana, Paula
  • Chaikuad, Apirat
  • Cuevas, Eva P.
  • Knapp, Stefan
  • Lietha, Daniel
  • Ramírez, David
  • Petralla, Sabrina
  • Monti, B.
  • Gil, Carmen
  • Martín-Requero, Ángeles
  • Palomo, Valle
  • De Lago, E.
  • Martínez Gil, Ana
68 p.-16 fig.-4 tab.+8 fig. supl.-5 tab. supl., Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease without any effective treatment. Protein TDP-43 is a pathological hallmark of ALS in both sporadic and familiar patients. Post-translational modifications of TDP-43 promote its aggregation in the cytoplasm. Tau-Tubulin kinase (TTBK1) phosphorylates TDP-43 in cellular and animal models; thus, TTBK1 inhibitors emerge as a promising therapeutic strategy for ALS. The design, synthesis, biological evaluation, kinase–ligand complex structure determination, and molecular modeling studies confirmed novel pyrrolopyrimidine derivatives as valuable inhibitors for further development. Moreover, compound 29 revealed good brain penetration in vivo and was able to reduce TDP-43 phosphorylation not only in cell cultures but also in the spinal cord of transgenic TDP-43 mice. A shift to M2 anti-inflammatory microglia was also demonstrated in vivo. Both these activities led to motor neuron preservation in mice, proposing pyrrolopyrimidine 29 as a valuable lead compound for future ALS therapy., This work was supported by Comunidad de Madrid (grant B2017/BMD-3813), the European Social Fund+ (ESF+), MINECO (Grants SAF2016-76693-R to A.M., RTI2018-0988885-B-I00 to E.d.L., and CTQ2015-66313-R to A.M.R.), AIE (RTI2018-099318-B-I00 to D.L., cofunded by the European Regional Development Fund (FEDER)), ISCiii CIBERNED (CB18/05/00040 to A.M., V.P., and A.M.R. and CB06/05/0089 to E.dL.), MECD (FPU16/04466 to V.N.), Cost Action CA15135 “MuTaLig” (COST-STSM-CA15135-37514 to L.M.G.), FONDECYT (Grant 11180604 to D.R.). V.P. has received financial support through the Postdoctoral Junior Leader Fellowship Program (LCF/BQ/PR18/11640007) from “la Caixa” Banking Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A tethered ligand assay to probe SARS-CoV-2:ACE2 interactions

  • Bauer, Magnus Sebastian
  • Gruber, Sophia
  • Hausch, Adina
  • Gomes, Priscila S. F. C.
  • Milles, Lukas Frederik
  • Nicolaus, Thomas
  • Schendel, Leonard C.
  • López-Navajas, Pilar
  • Procko, Erik
  • Lietha, Daniel
  • Melo, Marcelo C. R.
  • Bernardi, Rafael C.
  • Gaub, Hermann Eduard
  • Lipfert, Jan
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are initiated by attachment of the receptor-binding domain (RBD) on the viral Spike protein to angiotensin-converting enzyme-2 (ACE2) on human host cells. This critical first step occurs in dynamic environments, where external forces act on the binding partners and avidity effects play an important role, creating an urgent need for assays that can quantitate SARS-CoV-2 interactions with ACE2 under mechanical load. Here, we introduce a tethered ligand assay that comprises the RBD and the ACE2 ectodomain joined by a flexible peptide linker. Using magnetic tweezers and atomic force spectroscopy as highly complementary single-molecule force spectroscopy techniques, we investigate the RBD:ACE2 interaction over the whole physiologically relevant force range. We combine the experimental results with steered molecular dynamics simulations and observe and assign fully consistent unbinding and unfolding events across the three techniques, enabling us to establish ACE2 unfolding as a molecular fingerprint. Measuring at forces of 2 to 5 pN, we quantify the force dependence and kinetics of the RBD:ACE2 bond in equilibrium. We show that the SARS-CoV-2 RBD:ACE2 interaction has higher mechanical stability, larger binding free energy, and a lower dissociation rate compared to SARS-CoV-1, which helps to rationalize the different infection patterns of the two viruses. By studying how free ACE2 outcompetes tethered ACE2, we show that our assay is sensitive to prevention of bond formation by external binders. We expect our results to provide a way to investigate the roles of viral mutations and blocking agents for targeted pharmaceutical intervention., This study was supported by German Research Foundation Projects 386143268 and 111166240, a Human Frontier Science ProgramCross Disciplinary Fellowship (LT000395/2020C) and European Molecular Biology Organization Non-Stipendiary long-term fellowship (ALTF 1047-2019) to L.F.M., and the Physics Department of LMU Munich. R.C.B. and P.S.F.C.G. are supported by start-up funds provided by Auburn University, and D.L. acknowledges support from the Spanish Ministry of Science, Innovation and Universities for the Spanish State Research Agency Retos Grant RTI2018- 099318-B-I00, cofunded by the European Regional Development Fund., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New insights into FAK structure and function in focal adhesions

  • Le Coq, Johanne
  • Acebrón, Iván
  • Rodrigo Martín, Bárbara
  • López-Navajas, Pilar
  • Lietha, Daniel
10 p.-4 fig., Focal adhesion kinase (FAK; also known as PTK2) was discovered three decades ago and is now recognised as a key player in the regulation of cell–matrix adhesion and mesenchymal cell migration. Although it is essential during development, FAK also drives invasive cancer progression and metastasis. On a structural level, the basic building blocks of FAK have been described for some time. However, a picture of how FAK integrates into larger assemblies in various cellular environments, including one of its main cellular locations, the focal adhesion (FA) complex, is only beginning to emerge. Nano-resolution data from cellular studies, as well as atomic structures from reconstituted systems, have provided first insights, but also point to challenges that remain for obtaining a full structural understanding of how FAK is integrated in the FA complex and the structural changes occurring at different stages of FA maturation. In this Review, we discuss the known structural features of FAK, the interactions with its partners within the FA environment on the cell membrane and propose how its initial assembly in nascent FAs might change during FA maturation under force., D.L. is funded by the Ministerio de Ciencia, Innovación y Universidades for the Spanish State Research Agency Retos (grant RTI2018-099318-B-I00), and from the Ministerio de Ciencia e Innovación for the Generation of Knowledge (grant PID2021-127058NB-I00), both co-funded by the European Regional Development Fund (FEDER)., Peer reviewed